ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos2.14 B1.58 B1.71 B1.79 B2.18 B7.27 BInvestigación y desarrollo3.19 B2.26 B2.58 B2.53 B2.59 B9.95 BBeneficio operativo-1.91 B7.03 B7.83 B7.82 B4.9 B27.59 BTotal de ingresos no operativos-849 M-348 M-400 M641 M578 M471 MGastos por intereses, netos de intereses capitalizados496 M494 M485 M480 M432 M1.89 BIngresos no operativos, una vez deducidos los gastos por intereses-1.04 B-503 M-391 M53 M95 M-746 MIngresos/gastos extraordinarios-305 M-339 M-494 M108 M51 M-674 MBeneficio antes de impuestos175 M2.97 B1.77 B3.11 B1.47 B9.33 BParticipación en los beneficios8 M-9 M-37 M-6 M99 M47 MImpuestos99 M509 M460 M919 M384 M2.27 BParticipación minoritaria——————Otros ingresos/gastos después de impuestos29 M-10 M12 M74 M-308 M-232 MBeneficio neto antes de actividades interrumpidas72 M2.46 B1.31 B2.2 B1.09 B7.05 BOperaciones suspendidas——————Beneficio neto72 M2.46 B1.31 B2.2 B1.09 B7.05 BAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas72 M2.46 B1.31 B2.2 B1.09 B7.05 BBeneficio básico por acción0.051.210.641.080.543.47Beneficio por acción diluido0.051.20.641.080.543.46Número medio de acciones ordinarias2.03 B2.03 B2.04 B2.04 B2.03 B8.14 BAcciones diluidas2.03 B2.04 B2.04 B2.04 B2.04 B8.16 BEBITDA2.06 B3.98 B2.78 B4.13 B2.45 B13.34 BEBIT175 M2.97 B1.77 B3.11 B1.47 B9.33 BCosto de los ingresos4.81 B3.03 B3.37 B3.44 B4.1 B13.94 BOtros costes de producción——————Amortización y depreciación (flujo de caja)1.88 B1.01 B1.01 B1.01 B977 M4.01 B
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.